Information Provided By: 
Fly News Breaks for September 15, 2015
ICPT
Sep 15, 2015 | 10:45 EDT
Yesterday, Intercept Pharmaceuticals released Phase 3 REGENERATE trial protocol on clinicaltrials.gov. Morgan Stanley analyst Andrew Berens said the Phase 3 OCA trial protocol excludes patients with elevated LDL, mild renal insufficiency, specific types of cardiovascular disease, and uncontrolled diabetes. Berens' analysis indicates half the NASH population may not be candidates for OCA based on the criteria and the exclusion criteria my pose a risk to the firm's NASH revenue forecast. Morgan Stanley rates shares an Underweight.
News For ICPT From the Last 2 Days
There are no results for your query ICPT
